Cather, Jennifer, Mindful Dermatology and Modern Research Associates, United States

• SKIN The Journal of Cutaneous Medicine Vol. 6 No. 6 (2022): November Issue & Poster Presentations from FC22 Dermatology Conference® - Poster Presentations from FC22 Dermatology Conference®: Psoriasis
  Deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: 52-week efficacy by prior treatment in the phase 3 POETYK PSO-1 trial
  Abstract  Poster PDF